Newsbot

Anthropic unveils Claude Opus 5.5

Anthropic on Tuesday launched Claude Opus 5.5, a new AI model that it says delivers performance comparable to its top-tier Fable 5.1 while ?costing 40% less to run than its predecessor.

Siegeszug von Tesla, BYD & Co?

Gute Aussichten für E-Auto-Hersteller wie Tesla und BYD: Der Anteil rein elektrisch betriebener Pkw an den Neuzulassungen in der Europäischen Union ist 2025 auf einen Rekordwert gestiegen. Nach Angaben des Statistischen Bundesamtes, das sich auf Eurostat-Daten beruft, entfielen 17,3 Prozent aller neu zugelassenen Fahrzeuge auf Elektroautos.

Xer Tech Holding AB Announces Martin Lidgren’s Decision to Step Down from the Board of Directors

Xer Tech Holding AB (publ) announces that Martin Lidgren has informed the Board of Directors of his decision to step down from his position as a member of the Board with immediate effect, following the recent birth of his daughter.The decision has been made to allow Martin to take parental leave and dedicate more time to his family. The Board of Directors does not currently intend to appoint an immediate replacement for Martin and will continue to operate with its existing members.Martin has ...

Buy-back of shares in MTG during week 38, 2026

During the period between 14 September 2026 and 18 September 2026 Modern Times Group MTG AB (publ) (LEI code 549300E8NDODRSX29339) (“MTG”) repurchased, in total, 68 000 own class B shares (ISIN code SE0018012494) under the share repurchase program initiated by the Board of Directors.The share buy-backs form a part of the share repurchase program of a maximum amount of SEK 500 million, which MTG announced on 21 May 2026. The share repurchase program, which runs from 22 May 2026 up until and incl...

ShaMaran Announces Annual Meeting Voting Results

Hamilton, Bermuda, September 22, 2026 /CNW/ - ShaMaran Petroleum Ltd. (“ShaMaran” or the “Company”) (Euronext Growth Oslo: SNM) (Nasdaq First North Stockholm: SNM) held its annual general meeting of shareholders in Hamilton, Bermuda today, and all resolutions were passed.Shareholders voted as follows on the matters before the meeting:Election of DirectorsShareholders elected the following five (5) board members to serve on the Company’s board of directors until the next annual meeting of s...

CEO Chat with Dr. Ragula Bhaskar, Chairman and CEO, and Kanishka Ragula, CFO of FatPipe, Inc.

NASDAQ: FATNLisa Thompson: Hi everyone, Im Lisa Thompson, Senior Technology Analyst with Zacks Small Cap Research, and welcome to another episode of our CEO Chat. Today we have the Chairman and CEO of FatPipe Networks (NASDAQ: FATN), Dr. Ragula Bhaskar, as well as Kanishka Ragula, who is the newly appointed CFO, here to answer our questions and to talk a little bit about whats going on at the company. Dr. Bhaskar, will you please start off? And tell us about the company and what you do.Dr. ...

Xi in Washington: Roter Teppich für den Rivalen

Donald Trump fährt am Mittwoch selbst zum Flughafen, wenn Xi Jinping auf der Joint Base Andrews landet. Es ist Xis erster Staatsbesuch in Washington seit 2015 und das Rückspiel zu Trumps Peking-Reise im Mai. Am Donnerstag folgen die Begrüßung auf dem Südrasen, eine Truppenparade im Rosengarten, das bilaterale Treffen und am Abend das Bankett mit der Tech-Elite.

Bulletin from the Extraordinary General Meeting in Hansa Biopharma AB (publ)

Lund, Sweden, September 22, 2026. Hansa Biopharma AB (publ), “Hansa” (Nasdaq Stockholm: HNSA), has today on September 22, 2026 held its Extraordinary General Meeting. The Extraordinary General Meeting was held by physical presence of shareholders and with the option for shareholders to exercise their voting rights by advance voting (postal voting). The Extraordinary General Meeting of Hansa passed the following resolutions.The number of members of the Board of Directors, election of new member...

BDRX: Enrollment in Phase 3 SERENTA Trial Reaches 92 Patients

By David Bautz, PhDNASDAQ: BDRXREAD THE FULL BDRX RESEARCH REPORTBusiness UpdateEnrollment Continues in Phase 3 SERENTA Trial Biodexa Pharmaceuticals, PLC (NASDAQ: BDRX) is conducting the Phase 3 SERENTA trial of MTX230 (eRAPA) in patients with familial adenomatous polyposis (FAP). It is a double blind, placebo controlled trial that will enroll 168 high-risk patients with germline or phenotypic FAP diagnosis (NCT06950385). Patients are randomized 2:1 drug/placebo to evaluate the safety and...